. 2014 Aug;24(8):899-900.

doi: 10.1038/cr.2014.90. Epub 2014 Jul 8.

BETs abet Tam-R in ER-positive breast cancer

Prasanna G Alluri¹, Irfan A Asangani², Arul M Chinnaiyan³

Affiliations

¹ 1] Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
² 1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
³ 1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA [3] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [4] Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [5] Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

PMID: 25001387
PMCID: PMC4123300
DOI: 10.1038/cr.2014.90

BETs abet Tam-R in ER-positive breast cancer

Prasanna G Alluri et al. Cell Res. 2014 Aug.

. 2014 Aug;24(8):899-900.

doi: 10.1038/cr.2014.90. Epub 2014 Jul 8.

Authors

Prasanna G Alluri¹, Irfan A Asangani², Arul M Chinnaiyan³

Affiliations

¹ 1] Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
² 1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
³ 1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA [3] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [4] Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [5] Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

PMID: 25001387
PMCID: PMC4123300
DOI: 10.1038/cr.2014.90

Abstract

Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers. Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers, including tamoxifen-resistant breast cancer.

PubMed Disclaimer

Figures

**Figure 1**
Context-dependent roles of BRD proteins in breast and prostate cancers. Bromodomain proteins play a key role in transcriptional regulation by interacting with acetylated histones and oncogenic drivers such as WHSC1, AR and TWIST. BET inhibitors cause preferential loss of BRD proteins at “super-enhancers” associated with key oncogenic drivers and may have therapeutic benefit in the treatment of tamoxifen-resistant breast cancer, triple negative breast cancer and castration-resistant prostate cancer.

See this image and copyright information in PMC

Cited by

Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo.
Huang QX, Fan DM, Zheng ZZ, Ran T, Bai A, Xiao RQ, Hu GS, Liu W. Huang QX, et al. J Med Chem. 2024 Apr 25;67(8):6658-6672. doi: 10.1021/acs.jmedchem.4c00141. Epub 2024 Apr 3. J Med Chem. 2024. PMID: 38569135 Free PMC article.
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Xie F, Huang M, Lin X, Liu C, Liu Z, Meng F, Wang C, Huang Q. Xie F, et al. Sci Rep. 2018 May 25;8(1):8102. doi: 10.1038/s41598-018-26496-0. Sci Rep. 2018. Retraction in: Sci Rep. 2023 Nov 28;13(1):20934. doi: 10.1038/s41598-023-48298-9. PMID: 29802402 Free PMC article. Retracted.
TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers.
Serandour AA, Mohammed H, Miremadi A, Mulder KW, Carroll JS. Serandour AA, et al. Oncogene. 2018 Sep;37(39):5281-5291. doi: 10.1038/s41388-018-0312-2. Epub 2018 Jun 12. Oncogene. 2018. PMID: 29895970 Free PMC article.
Acetylation of histone H3K27 signals the transcriptional elongation for estrogen receptor alpha.
Gao Y, Chen L, Han Y, Wu F, Yang WS, Zhang Z, Huo T, Zhu Y, Yu C, Kim H, Lee M, Tang Z, Phillips K, He B, Jung SY, Song Y, Zhu B, Xu RM, Feng Q. Gao Y, et al. Commun Biol. 2020 Apr 7;3(1):165. doi: 10.1038/s42003-020-0898-0. Commun Biol. 2020. PMID: 32265480 Free PMC article.
The changing role of ER in endocrine resistance.
Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. Nardone A, et al. Breast. 2015 Nov;24 Suppl 2(0 2):S60-6. doi: 10.1016/j.breast.2015.07.015. Epub 2015 Aug 10. Breast. 2015. PMID: 26271713 Free PMC article. Review.

See all "Cited by" articles

References

1. Early Breast Cancer Trialists' Collaborative G. Lancet. 2005;365:1687–1717. - PubMed
1. Roop RP, Ma CX. Future Oncol. 2012. pp. 273–292. - PubMed
1. Filippakopoulos P, Qi J, Picaud S, et al. Nature. 2010. pp. 1067–1073. - PMC - PubMed
1. Dawson MA, Prinjha RK, Dittmann A, et al. Nature. 2011. pp. 529–533. - PMC - PubMed
1. Feng Q, Zhang Z, Shea MJ, et al. Cell Res. 2014. pp. 809–819. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

BETs abet Tam-R in ER-positive breast cancer

Affiliations

BETs abet Tam-R in ER-positive breast cancer

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Abstract

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous